Will Medicare cover Alzheimer’s drugs like Aduhelm? That decision-making process is underway. This week, the U.S. government embarked on the formal review process to…
The FDA will hasten the review of two more new Alzheimer’s drug candidates, Eli Lilly & Co.’s donanemab and Biogen and Eisai’s lecanemab. Today,…
After much controversy, more resignations in protest against the FDA accelerated approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab). In a bold act of protest…
Looking for answers about Alzheimer’s treatment Aduhelm (generic name aducanumab)? Here’s a primer on what it is, what it does, and more, according to…
Dementia advocacy groups including UsAgainstAlzheimer’s, American Heart Association, Volunteers of America, National Consumers League, American Public Health Association, Alzheimer’s Association, Trust for America’s Health…
With the #MoreTime campaign, the Alzheimer’s Association has gone all in on aducanumab, the controversial new Alzheimer’s drug produced by Biogen and Eisai. With…
A new approach to genome sequencing newly identifies 13 rare gene variants potentially associated with Alzheimer’s. Dr. Rudy Tanzi, vice chair of neurology and…